PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024
Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.